Prof. Elad Jacoby, MD
Global Leader in Pediatric Hemato-Oncology, CAR-T Therapy & Bone Marrow Transplantation
About Prof. Elad Jacoby
Prof. Elad Jacoby is one of the world’s leading experts in pediatric hemato-oncology and advanced cellular therapies, serving as the Head of the Pediatric Cell Therapy Center and Medical Director of the Advanced Biotherapy Center at Sheba Medical Center. With nearly two decades of clinical and research experience, he is widely recognized for transforming the treatment landscape for children with complex and treatment-resistant blood cancers.
Prof. Jacoby is a pioneer of CAR-T cell therapy in Israel, having led the implementation of one of the first national programs for pediatric leukemia. His work focuses on delivering highly personalized, cutting-edge therapies to children who often have limited or no remaining standard treatment options.
Beyond his clinical leadership, he is an Associate Professor at Tel Aviv University, actively involved in training the next generation of physicians while leading groundbreaking international research in immunotherapy and cellular medicine.
Clinical Expertise & Special Focus
Prof. Jacoby specializes in the most advanced and life-saving treatments for children and young patients with hematologic malignancies, including:
- CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cells)
Personalized immunotherapy designed to reprogram the patient’s immune system to fight cancer - Bone Marrow & Stem Cell Transplantation (BMT)
Including complex and high-risk transplant cases - Pediatric Leukemia & Lymphoma
Acute lymphoblastic leukemia (ALL), relapsed/refractory leukemias, and aggressive lymphomas - Advanced Cellular Immunotherapy
Including anti-viral T-cell therapies for immunocompromised patients - Mitochondrial Augmentation Therapy (MAT)
First-in-human innovative treatments for rare and complex conditions
His approach combines precision medicine, immunotherapy, and transplantation, allowing for comprehensive, individualized care even in the most challenging cases.
Innovation & Research Leadership
Prof. Jacoby is at the forefront of global innovation in pediatric cancer care. He leads and participates in international clinical trials focused on next-generation therapies, including:
- CAR-T therapies for resistant leukemias and lymphomas
- Novel cellular therapies targeting cancer and severe infections
- Breakthrough research in mitochondrial medicine and immune system modulation
He has authored over 240 scientific publications in leading medical journals and collaborates with top institutions worldwide, including:
- Johns Hopkins Hospital (USA)
- National Cancer Institute (NCI), USA
- International pediatric oncology and CAR-T research networks
His research directly translates into real-world treatment options, giving patients access to therapies not widely available elsewhere.
Patient-Centered Approach
Prof. Jacoby is known not only for his clinical excellence but also for his deep commitment to patient-centered care. Every child and family receives:
- A fully personalized treatment plan tailored to the disease and patient profile
- Access to the most advanced therapies available globally
- Close monitoring by a multidisciplinary team of experts
- Compassionate guidance throughout every stage of treatment
His philosophy is simple: combine innovation with empathy, ensuring that families feel supported, informed, and confident in their care journey.
Leadership & Roles
- Head, Pediatric Cell Therapy Center, Sheba Medical Center
- Medical Director, Advanced Biotherapy Center, Sheba Medical Center
- Senior Lecturer / Associate Professor, Tel Aviv University School of Medicine
- Member, CAR-T Cell Taskforce (IBFM Study Group)
- Member, Institutional Review Board, Sheba Medical Center
Education & International Training
- MD, Tel Aviv University School of Medicine
- Pediatrics Residency, Sheba Medical Center
- Fellowship in Pediatric Hematology & Oncology, Johns Hopkins Hospital, USA
- Clinical & Research Fellowship, National Cancer Institute (NCI), USA
Board Certifications
- Pediatrics
- Pediatric Hematology & Oncology
Why Patients Choose Prof. Elad Jacoby
- Pioneer of pediatric CAR-T therapy in Israel
- Leader in integrating CAR-T with bone marrow transplantation
- Access to exclusive clinical trials and next-generation treatments
- Extensive experience in complex and relapsed cases
- Internationally recognized expert with a strong academic and research background
- Dedicated to delivering hope through innovation and personalized care
A Leader in the Future of Pediatric Cancer Care
Through his work, Prof. Jacoby continues to redefine what is possible in treating childhood cancers—bringing together science, innovation, and compassionate care to improve outcomes and give new hope to patients and their families worldwide.